康哲藥業(00867.HK)年度溢利升30.7%至25.56億元 末期息0.2033元
格隆匯 3 月 16日丨公佈年度業績，截至2020年12月31日止年度，營業額增長14.4%至人民幣69.460億元；若將"兩票制"收入還原則營業額增長15.4%至人民幣79.573億元；毛利增長12.9%至人民幣51.342億元；若將"兩票制"收入還原則毛利增長16.0%至人民幣48.427億元；年度溢利增長30.7%至人民幣25.557億元；正常化年度溢利增長18.4%至人民幣26.961億元，每股基本盈利1.0237元，擬派末期息每股人民幣0.2033元。
於報吿期內，集團經營業績實現良好增長，同時在創新管線擴展、臨牀開發推進及大健康業務佈局等方面取得重大進展，摘要如下：
創新管線持續擴充
•獲得亞甲藍MMX在中國大陸、港、澳、台的獨家授權權利，該產品為增強結直腸癌或癌前病變診斷敏感性的口服亞甲藍緩釋製劑。
•獲得甲氨蝶呤預充式注射器/注射筆在中國大陸、港、澳、台的獨家授權權利，該產品有望成為中國市場首個皮下給藥途徑治療RA的MTX預充式注射劑。
•獲得膀胱灌注用卡介苗在中國大陸、港、澳的獨家授權權利，該產品為多國唯一可用的膀胱內治療用卡介苗製劑。
•獲得PLENITY®在中國大陸、港、澳、台及新加坡、阿拉伯聯合酋長國的獨家授權權利，該產品為美國FDA批准的由天然來源材料製成的安全有效的口服體重管理產品。
•獲得德度司他片在中國大陸、港、澳、台的獨家授權權利，該產品用於治療慢性腎病患者的貧血，是受專利保護的新分子實體，為口服低氧誘導因子脯氨醯羥化酶抑制劑(HIF-PHI)。
創新產品中國臨牀開發快速推進
•地西泮鼻噴霧劑的註冊性試驗完成全部受試者給藥及血樣採集工作，該產品為居家便捷、快速起效，針對六歲及以上人羣急性反覆性癲癇發作的創新藥。
•0.09%環孢素滴眼液的註冊性試驗完成首例受試者給藥，該產品為無防腐劑、基於全球納米技術專利保護的創新眼用製劑。
•替拉珠單抗注射液的註冊性試驗完成首例受試者給藥，該產品為特異性靶向IL-23的單克隆抗體。?德度司他片(1類新藥)的臨牀試驗申請獲中國NMPA受理。
大健康跨境電商業務正式開啟
•"康哲健康海外旗艦店"正式入駐京東國際和有贊商城，截至2020年12月31日，已有來自4個歐洲知名品牌的18款優質產品上線銷售。
報吿期內，集團研發開支總額增加35.0%，達到人民幣5.273億元，去年同期為人民幣3.905億元；研發開支總額佔營業額比率為7.6%，較去年同期的6.4%增加1.2個百分點。若將"兩票制"收入還原則集團報吿期研發開支總額佔營業額比率為6.6%，較去年同期的5.7%增加0.9個百分點，主要反映新產品管線的擴充和新產品臨牀開發活動的增加。
此外，於2020年12月31日，銀行結餘及現金為人民幣26.684億元，可隨時變現的銀行承兑匯票為人民幣4.460億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
